CG Oncology, Inc. (NASDAQ:CGON) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of CG Oncology, Inc. (NASDAQ:CGON) have been given a consensus recommendation of “Moderate Buy” by the fourteen research firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $81.7273.

A number of research firms have issued reports on CGON. JPMorgan Chase & Co. raised their price target on shares of CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Royal Bank Of Canada increased their price objective on shares of CG Oncology from $79.00 to $81.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Wolfe Research started coverage on shares of CG Oncology in a report on Tuesday, May 19th. They set a “peer perform” rating for the company. Truist Financial restated a “buy” rating and set a $82.00 target price (up from $77.00) on shares of CG Oncology in a research report on Thursday, May 14th. Finally, Wall Street Zen lowered shares of CG Oncology from a “hold” rating to a “sell” rating in a report on Saturday, April 25th.

Insider Activity

In related news, Director James Mulay sold 15,600 shares of the company’s stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $73.01, for a total value of $1,138,956.00. Following the completion of the transaction, the director owned 15,600 shares of the company’s stock, valued at approximately $1,138,956. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Leonard E. Post sold 1,000 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $54.50, for a total transaction of $54,500.00. Following the transaction, the director owned 1,000 shares of the company’s stock, valued at $54,500. This represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On CG Oncology

A number of large investors have recently made changes to their positions in the stock. AQR Capital Management LLC acquired a new stake in CG Oncology during the first quarter worth $475,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of CG Oncology by 18.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,522 shares of the company’s stock valued at $876,000 after purchasing an additional 5,442 shares during the last quarter. Millennium Management LLC grew its holdings in shares of CG Oncology by 139.4% during the 1st quarter. Millennium Management LLC now owns 596,056 shares of the company’s stock worth $14,597,000 after purchasing an additional 347,055 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of CG Oncology by 42.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 179,363 shares of the company’s stock worth $4,393,000 after purchasing an additional 53,461 shares during the last quarter. Finally, Legal & General Group Plc increased its position in shares of CG Oncology by 12.3% during the 2nd quarter. Legal & General Group Plc now owns 44,354 shares of the company’s stock worth $1,153,000 after purchasing an additional 4,847 shares during the last quarter. 26.56% of the stock is currently owned by hedge funds and other institutional investors.

CG Oncology Stock Performance

CG Oncology stock opened at $59.56 on Monday. The business’s 50-day simple moving average is $65.05 and its two-hundred day simple moving average is $56.63. The company has a market cap of $5.25 billion, a PE ratio of -25.56 and a beta of 0.31. CG Oncology has a fifty-two week low of $23.65 and a fifty-two week high of $75.50.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The firm had revenue of $1.08 million during the quarter, compared to analysts’ expectations of $0.45 million. As a group, analysts predict that CG Oncology will post -2.89 EPS for the current fiscal year.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.